Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 1Unknown 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 85Breast Neoplasms 37Lung Neoplasms 27Triple Negative Breast Neoplasms 25Ovarian Neoplasms 21Squamous Cell Carcinoma of Head and Neck 20Fallopian Tube Neoplasms 16Small Cell Lung Carcinoma 15Neoplasm Metastasis 14Endometrial Neoplasms 13Esophageal Neoplasms 11Neoplasms 10Prostatic Neoplasms 9Colorectal Neoplasms 9Head and Neck Neoplasms 8Carcinoma 8Urinary Bladder Neoplasms 7Uterine Cervical Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Pancreatic Neoplasms 6Oropharyngeal Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Laryngeal Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Squamous Cell 5Stomach Neoplasms 4Mouth Neoplasms 4Melanoma 4Carcinoma, Ovarian Epithelial 4Urothelial Cancer 3

Interventions

pertuzumab 3Trastuzumab 3Paclitaxel 2Docetaxel 2tucatinib 1trastuzumab deruxtecan 1pegfilgrastim 1atezolizumab 1Carboplatin 1Ado-Trastuzumab Emtansine 1ARX788 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × HER2-positive Breast Cancer × Carboplatin × Clear all
NCT05426486 2024-10-30

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Shengjing Hospital

Phase 2/3 Active not recruiting
136 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡